Afasevikumab, also known as RG 7624, RO 5553110, and NI-1401, is a fully human monoclonal IgG1?? antibody designed to neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). This antibody exhibits potent anti-inflammatory properties by targeting and inhibiting the activity of these cytokines, which are crucial mediators in the pathogenesis of various inflammatory and autoimmune disorders. Afasevikumab is primarily utilized in research focused on the therapeutic potential in treating conditions characterized by excessive or aberrant IL-17 activity.
Afasevikumab, also known as RG 7624, RO 5553110, and NI-1401, is a fully human monoclonal IgG1?? antibody designed to neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). This antibody exhibits potent anti-inflammatory properties by targeting and inhibiting the activity of these cytokines, which are crucial mediators in the pathogenesis of various inflammatory and autoimmune disorders. Afasevikumab is primarily utilized in research focused on the therapeutic potential in treating conditions characterized by excessive or aberrant IL-17 activity.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
